Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genetic and Clinical Factors Associated With Metformin Plasma Concentrations Following an Acute Metformin Challenge.

The Journal of clinical endocrinology and metabolism·2026

Same author

Beyond one-size-fits-all metformin dosing in youth.

Pediatric research·2026

Same author

Quantifying the Effect of Fat and Protein on the Postprandial Glucose Excursion in Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System.

Journal of diabetes science and technology·2026

Same author

Integrating the Glycemia Risk Index Into Clinical Practice and Research: A Consensus Report.

Journal of diabetes science and technology·2026

Same author

Research Code Sharing in Support of Gold Standard Science.

Journal of diabetes science and technology·2026

Same author

Novel Phenotypic Clusters of Youth-Onset Type 2 Diabetes Offer No Added Prognostic Value to Simple Clinical Measures.

Diabetes care·2025

Search research articles

Related Experiment Video

Updated: Oct 26, 2025

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Adjunctive Therapies to Optimize Closed-loop Glucose Control.

Shylaja Srinivasan¹, Laya Ekhlaspour², Eda Cengiz³

¹Division of Pediatric Endocrinology and Diabetes, University of San Francisco, CA, USA.

Journal of Diabetes Science and Technology

|July 28, 2021

Summary

This summary is machine-generated.

Closed-loop insulin systems improve type 1 diabetes management. Adjunct treatments, using type 2 diabetes medications, further enhance glycemic control by addressing missing physiological factors beyond insulin.

Keywords:

GLP-1 agonist adjunctive therapy artificial pancreas closed-loop system glucagon insulin

More Related Videos

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli

Published on: August 12, 2016

Quantitative and Temporal Control of Oxygen Microenvironment at the Single Islet Level

Quantitative and Temporal Control of Oxygen Microenvironment at the Single Islet Level

Published on: November 17, 2013

Related Experiment Videos

Last Updated: Oct 26, 2025

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli

Published on: August 12, 2016

Quantitative and Temporal Control of Oxygen Microenvironment at the Single Islet Level

Quantitative and Temporal Control of Oxygen Microenvironment at the Single Islet Level

Published on: November 17, 2013

Area of Science:

Endocrinology
Metabolic Diseases
Diabetes Technology

Background:

Closed-loop insulin delivery systems are increasingly standard for type 1 diabetes, improving glycemic control.
Further optimization is needed to achieve target glycemic control and enhance patient outcomes.
Adjunct therapies are emerging to complement insulin-only approaches.

Purpose of the Study:

To review adjunct treatment agents for closed-loop systems in type 1 diabetes.
To explore mechanisms, benefits, and side effects of these adjunct therapies.
To evaluate the evidence supporting their use in conjunction with closed-loop treatment.

Main Methods:

Literature review of adjunct therapies for closed-loop insulin delivery.
Analysis of mechanisms of action for medications targeting glycemic regulation.
Synthesis of clinical trial data and patient-reported outcomes.

Main Results:

Adjunct agents, often approved for type 2 diabetes, address missing entero-endocrine regulation.
These therapies aim to improve clinical outcomes and patient-reported results.
Evidence supports their potential to enhance closed-loop system performance.

Conclusions:

Adjunct treatments offer a promising strategy to optimize closed-loop insulin delivery for type 1 diabetes.
These therapies can help overcome challenges in achieving ideal glycemic control.
Further research is warranted to fully integrate adjunct therapies into standard care.